Gilead Sciences Shoots for 1st All-Oral Hepatitis C Regimen

Four months after passing on an opportunity to pursue Phase III trials of its hepatitis C drug GS-7977 in combination with Bristol-Myers Squibb Co.'s daclatasvir, Gilead Sciences Inc. has confirmed that it will go it alone instead, pressing ahead with its in-house NS5A inhibitor GS-5885.